Relationship of Structure to Biodistribution of Technetium Complexes. Tc/Re complexes for Sigma Receptor Studies in Oncology. Sigma 1 and sigma 2 binding sites are expressed in high density in a wide variety of human and rodent tumor cell lines. Technetium-99m (Tc-99m) radiopharmaceuticals are utilized widely in the clinical diagnosis and prognosis of disease. Tc-99m is generator produced, inexpensive, and available world-wide. It is ideal for imaging studies due to a favorable half-life (6.02 hr) and energy of the single gamma photon (140 KeV). In vivo detection of cancerous cells containing sigma receptors may be possible if high affinity, selective Tc-99m complexes can be identified. From the radionuclides considered for therapy, rhenium-186 (Re-186) and rhenium-188 (Re-188) possess suitable half lives and strong beta- emissions capable of delivering high doses to tissues. Both have a gamma photon (137 KeV, 9% and 155 KeV, 15%, respectively), making it possible to follow their biodistribution with the same scintigraphic equipment as used for Tc-99m. Therapeutic measures could be initiated upon substitution of Tc with either Re-186 or Re- 188. We propose to synthesize novel polyamine derivatives, based on high affinity compounds for the sigma- 1 and sigma- 2 binding sites, and prepare their corresponding Tc and Re complexes. Their biodistribution in mice in accord with normal distribution of sigma receptors will be assessed. Their affinity and specificity for the sigma-1 and sigma-2 binding sites will be assessed in vitro in guinea pig brain homogenates and rat liver homogenates, respectively. Ligands and complexes displaying high affinity (nM range) will be further assayed in vitro in selected cells lines. The most promising Tc complexes will be evaluated in tumor-bearing mice for diagnostic potential; and evaluation of the most promising Re complexes for their therapeutic value. Requirements for a Physician-sponsored IND will be completed on the compound(s) that display appropriate characteristics.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Madar, Igal; Bencherif, Badredin; Lever, John et al. (2007) Imaging delta- and mu-opioid receptors by PET in lung carcinoma patients. J Nucl Med 48:207-13
Lin, Kuo-Shyan; Luu, Andrew; Baidoo, Kwamena E et al. (2005) A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjug Chem 16:43-50
Hardwick, Matthew J; Chen, Ming-Kai; Baidoo, Kwamena et al. (2005) In vivo imaging of peripheral benzodiazepine receptors in mouse lungs: a biomarker of inflammation. Mol Imaging 4:432-8
Chen, Ming-Kai; Baidoo, Kwamena; Verina, Tatyana et al. (2004) Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain 127:1379-92
Lin, Kuo-Shyan; Luu, Andrew; Baidoo, Kwamena E et al. (2004) A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier. Bioconjug Chem 15:1416-23
Lever, J R; Ilgin, N; Musachio, J L et al. (1998) Autoradiographic and SPECT imaging of cerebral opioid receptors with an iodine-123 labeled analogue of diprenorphine. Synapse 29:172-82
Sanchez-Roa, P M; Wagner Jr, H N; Villemagne, V L et al. (1998) Effects of extracellular acetylcholine on muscarinic receptor binding assessed by [125I]dexetimide and a simple probe. Eur J Pharmacol 358:207-11
Baidoo, K E; Lin, K S; Zhan, Y et al. (1998) Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues. Bioconjug Chem 9:218-25
Baidoo, K E; Scheffel, U; Stathis, M et al. (1998) High-affinity no-carrier-added 99mTc-labeled chemotactic peptides for studies of inflammation in vivo. Bioconjug Chem 9:208-17
Kao, C H; Baidoo, K E; Lever, S Z (1997) Validation and application of a solid phase chemistry method for preparation of high effective specific activity technetium-99m radiopharmaceuticals. Nucl Med Biol 24:499-505

Showing the most recent 10 out of 88 publications